Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give Delcath an average recommendation of “Moderate Buy” (six analysts: five buy, one sell) with a 12-month average target of $22.50 and recent price targets ranging roughly $19–$30.
• Institutions own 61.12% of the company, with large stake increases from Rosalind Advisors (now ~3.3M shares), Geode, Vanguard and Goldman Sachs among others.
• Shares trade near $9.13 (50-day $9.61, 200-day $9.99) with a $317M market cap and high PE (~130); the company slightly beat the quarter’s EPS estimate ($-0.05 vs. -0.06) and reported $20.73M in revenue.

Shares of Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $22.50.

Several analysts recently issued reports on DCTH shares. Evercore set a $27.00 target price on Delcath Systems in a research note on Thursday, February 26th. BTIG Research dropped their price target on Delcath Systems from $23.00 to $19.00 and set a "buy" rating for the company in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Delcath Systems in a report on Monday, December 29th. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Delcath Systems in a research report on Friday, January 9th. Finally, Wall Street Zen downgraded shares of Delcath Systems from a "buy" rating to a "hold" rating in a report on Saturday, February 28th.

Institutional Trading of Delcath Systems

Several hedge funds have recently bought and sold shares of DCTH. Rosalind Advisors Inc. boosted its holdings in shares of Delcath Systems by 13.8% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company's stock valued at $44,885,000 after purchasing an additional 400,000 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Delcath Systems by 2.9% in the third quarter. Vanguard Group Inc. now owns 1,657,428 shares of the company's stock worth $17,817,000 after buying an additional 46,693 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Delcath Systems by 128.1% in the second quarter. Geode Capital Management LLC now owns 703,171 shares of the company's stock worth $9,565,000 after buying an additional 394,902 shares in the last quarter. Nantahala Capital Management LLC bought a new position in Delcath Systems during the third quarter valued at approximately $7,164,000. Finally, Goldman Sachs Group Inc. boosted its stake in Delcath Systems by 116.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company's stock valued at $5,936,000 after buying an additional 315,583 shares during the last quarter. Hedge funds and other institutional investors own 61.12% of the company's stock.

Delcath Systems Stock Performance

Shares of DCTH stock opened at $9.13 on Friday. The stock has a fifty day simple moving average of $9.61 and a two-hundred day simple moving average of $9.99. The firm has a market capitalization of $317.23 million, a PE ratio of 130.43 and a beta of 0.38. Delcath Systems has a 52-week low of $8.12 and a 52-week high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. Delcath Systems had a return on equity of 2.63% and a net margin of 3.17%.The business had revenue of $20.73 million for the quarter, compared to the consensus estimate of $20.35 million. On average, sell-side analysts forecast that Delcath Systems will post -0.79 EPS for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company's core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.